Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ventus Therapeutics
Biotech
Ventus to move daily oral lupus prospect into phase 2 testing
In a phase 1 study, VENT-03 “was safe and well-tolerated at doses far exceeding those planned for use in Phase 2 trials," the company said.
Eric Sagonowsky
Oct 31, 2024 9:10am
Novo enters NLRP3 arena, paying Ventus $70M for NASH hopeful
Sep 29, 2022 9:30am
Biogen CEO steps down after Aduhelm blunder—Chutes & Ladders
May 6, 2022 9:30am
Chasing Novartis and Roche, Ventus banks $140M for clinical work
Feb 9, 2022 8:12am
Ventus raises $100M to pursue NLRP3, crack undruggable targets
Apr 8, 2021 6:00am
Ventus uncloaks with $60M to target the innate immune system
May 6, 2020 7:00am
